when do glp 1 side effects subside GLP-1 Survey: 37.5% of People Stop GLP-1s after Just 3 Months Our number one frequently asked

One-way analysis of variance (ANOVA) and Tukeys post hoc test were used for parametric results

In the SURMOUNT-1 trial, the dual-acting medicine tirzepatide produced average reductions of roughly 16% to 22.5%, depending on dose

Conclusion: The Evolving Landscape of Weight Loss Treatment The development of GLP-1 medications, dual GIP/GLP-1 agonists, and emerging triple-agonist medications represents one of the most significant advances in obesity medicine in decades

Additionally, a University of Kentucky study identified a possible connection between long-term PFOS exposure and an increased risk of colorectal cancer, adding to the list of cancers linked to PFAS exposure

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 811 April 2024